A study testing whether a new weekly shot from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

Recruiting now. Registry record last updated August 20, 2026.

Who can join: Adults 18+, have obesity or are overweight, BMI 27+.
What you take: olatorepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 18 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Regeneron PharmaceuticalsDrug olatorepatideClass GLP-1/GIPSites 5 USEnrollment target 360

What this study is for

Primary condition: Overweight or Obesity.

Full scientific study title: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes.

Who can join

Age18 and upSexAnyBMI27 to 45

Adults 18+, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR
BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol

Key exclusion criteria

Previous or current diagnosis of Type 1 or Type 2 diabetes at screening
Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol
Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol
History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones
History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

Where this trial is enrolling

This trial has 5 sites across 3 states. Contact a site coordinator directly to start screening.

Find a site near you

California1 site

Diablo Clinical Research - Flourish Research
Walnut Creek, California

Florida3 sites

K2 Medical Research Maitland LLC, Main Office
Maitland, Florida
Charter Research LLC - The Villages
The Villages, Florida
Clinical Site Partners, LLC DBA Flourish Research
Winter Park, Florida

Kentucky1 site

AMR Clinical - Lexington
Lexington, Kentucky

Follow this trial

We email you if NCT07685808 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: July 28, 2026. Expected completion: January 21, 2028. Last updated on ClinicalTrials.gov: August 20, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.